Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enavogliflozin in Type 2 Diabetic Nephropathy with Moderate Renal Impairment
NCT06606093Phase 3Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enavogliflozin in type 2 diabetes mellitus (T2DM), diabetic nephropathy (DN), sponsored by Daewoong Pharmaceutical. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT06606093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06606093.